MabVax Therapeutics Holdings Inc. (fka MBVXQ)

[Avispa]

https://seekingalpha.com/news/3293832-mabvax-hires-advisor-assist-exploring-strategic-alternatives-shares-10-percent

[ClayTrader]

* * $MBVX Video Chart 07-24-17 * *

Link to Video - click here to watch the technical chart video

[Joecanada13]

Keep going! Loaded @ .89!

[Airstock]

Time for the eagle to put its wings on and fly this baby to the moon.

[armxlx]

News! May be a good play today....don't forget to play the MOMO!

[zino]

lmafo...ty

[Homebrew]

Wolf of pennystocks Pump-N-Dump newsletter. Gets paid to pump stocks that are about to get get dumped.

[zino]

who is wolf?..tyia bro

[Homebrew]

Another Pump-N-Dump in the works. Wolf got $35,000 to pump this.

[murocman]

Conference call after market closes. Possible trial update and catalyst.

Murocman

[stocktrademan]

MBVX bullish 4.12

just watching this one
had a reverse split 1:7.4 on 8/17/2016



normal chart


log chart

[ringao]

In since before the split and uplist I received the same letter, probably the same, from the CEO... it worked I bought more. GLTALs

[Homebrew]

Got a Pumpy-McDumpy Email Promotion recently. Someone paid $20,000 to pump this.

[follow_me]

Plan to go in big in the morning.

[follow_me]

I believe that MBVX is a great mid to long term play

[follow_me]

Will be watching closely after conference

[follow_me]

Wow just a 3.78 million shares left in float!!

[kellyaemmerson]

DMPI (Del Mar Pharma) will be the next to run
HOLD your MBVX and BUY DMPI
KAE

[Rogerthat1]

Thx.

[BiotechValues]

Sorry for your loss.

[Rogerthat1]

Had a paid pump out this morning on this. I closed my small position for a tiny loss. Scratch. Glty.

[BiotechValues]

New Investor Presentation

I know it's early in development, but slide #13 is pretty amazing.

Should be well received at Rodman and Renshaw Global Investment Conference next week.

http://www.mabvax.com/resources/MabVax%20Presentation%20for%20Investors%20September%202016.pdf

[mick]

need to pps stated here, MabVax Therapeutics Holdings Inc. (MBVX)'

[mick]

is this ah 3-d company ????? 'MabVax Therapeutics Holdings Inc. (MBVX)'

no pps given here/

[BiotechValues]

Nice hints in August 11 10-Q filing that upcoming pr on Phase I trial will be positive

"Of the nine patients who have been dosed to date, five have been treated for three or more months and investigator observations have noted stable disease for a subset of those patients. We are continuing to escalate the drug dose to assess safety and reach an MTD and anticipate initiating the second portion of the trial where our drug is dosed in combination with chemotherapy in the fourth quarter of this year. We expect to have the preliminary results of this clinical trial later in the third quarter in 2016.”

Stable disease in a subset of patients- pancreatic cancer and "stable disease" are not usually found in the same sentence.

[Rogerthat1]

Nice summary Lloyd. I hold a small position here which I'll just let it ride into the data. I thought 2 phase I data coming up this quarter. End of sept. Read in the filings. Could be wrong. I sometimes mix up my bios lmao

[LloydDC]

Pretty good way to structure a RS if your going to do one imho. Warrants exercise $5.55 and & $6.29. OPKO offering/purchase price April 2015 was at $.75 split adjusted $5.55 coincidentally the same price as current warrants. Expecting data in the next quarter. If my numbers are right after the RS OPKO/ Frost own 2,092,702 shares of common and new investors with current offering own 1,127,859. Directors and officers own approx 386,926 shares. There are now total 5,363,198 common. Looks like insiders had a bit of participation in the offering with today's form 4s. Market cap at $27M. Interesting to watch the bid ask spread which has been as wide as 50 cents during the day. Three days on Nasdaq pretty stable price so far. Have to see what the data shows. But with low float, add a bit of volume and these can be fun.

[5TOP]

Hmmm, I didn't realize you could do both at the same time. Good to know. Thanks

[SQUINTZ76]

They did both. $4.80 ish.

[5TOP]

Sorry what was the opening price after r/s, not uplisting

[5TOP]

Did they perform thier R/S and uplisting simultaneously? And what was the opening price after uplisting?

[Rogerthat1]

I love Nasdaq

[Renee]

MBVX moved to the Nasdaq from the OTC:

http://otce.finra.org/DLDeletions

[Renee]

MBVX one for 7.4 reverse split:

http://otce.finra.org/DLSymbolNameChanges

[Rogerthat1]

Nice. This will spike IMO.

[LloydDC]

Market cap after split and Nasdaq up list should be approx $28M and company will have $10M cash. All warrants appear to be exercisable above current prices. 1,559,252 "A" warrants exercise at $5.55 and 1,559,252 "B" warrants at $6.29.

[Rogerthat1]

Great thx. It was late lol.

Two preliminary phase I data due by end of Sept. This might have a run here IMO. I've got my tickets.

[LloydDC]

Total shares originally offered were 1,299,376 @$4.81 proceeds of $6,250,000. It looks like it was increased to 1,559,252 shares offered at $4.81 for total proceeds of $7,500,000. These numbers are after the 1 for 7.4 reverse split. Total shares after split 5,790,032 or 8,908,536 if all warrants are exercised in the future. Nasdaq application was approved so all appears to be a green light to reverse split, close the offering, and begin trading to Nasdaq.

[Rogerthat1]

Dang it they upped their offering seems like went from 5 mil to 7.5 mil shares? Amendment to s1 out ah. Am I reading this correctly?

[Rogerthat1]

From 10Q

Clinical Product Development – Recent Updates

Phase I Clinical Trial of MVT-5873 (HuMab-5B1) – In March 2016, we announced the initiation of a phase I clinical trial of MVT-5873 for patients with locally advanced or metastatic adenocarcinoma of the pancreas (“PDAC”) or other CA19-9 positive malignancies. The CA19-9 target is expressed on more than 90% of pancreatic cancers and is a validated biomarker for the disease. The Company filed an Investigational New Drug (“IND”) application for this product on November 30, 2015, and received U.S. Food and Drug Administration (“FDA”) authorization to proceed with the study on December 24, 2015. The study is a phase I, open-label, multi-center, dose-escalation clinical trial. The primary objectives are to determine the safety, maximum tolerated dose (“MTD”), and the pharmacokinetics (“PK”) of MVT-5873. The phase I trial will also evaluate the tumor response rate based on RECIST 1.1 guidelines for standard tumor measurement and the duration of response of MVT-5873 as a single agent or in combination with a standard of care chemotherapy regimen. The study will enroll up to approximately 60 patients at multiple centers in the United States. In the dose escalation portion of the trial, patients enrolled have locally advanced or metastatic pancreatic cancer who have failed other therapies. Nine patients treated to date have been observed as tolerating initial dosages of the drug reasonably well. Infusion reactions, which are not uncommon with protein drugs, have been the most frequent adverse events related to drug exposure and have been addressed by slowing the infusion rate. Of the nine patients who have been dosed to date, five have been treated for three or more months and investigator observations have noted stable disease for a subset of those patients. We are continuing to escalate the drug dose to assess safety and reach an MTD and anticipate initiating the second portion of the trial where our drug is dosed in combination with chemotherapy in the fourth quarter of this year. We expect to have the preliminary results of this clinical trial later in the third quarter in 2016, with full results expected in 2017.

Phase I Clinical Trial of MVT-2163 ([89Zr]-HuMab-5B1) – In July 2016, we announced the initiation of a phase I clinical trial of MVT-2163 as a new generation PET imaging agent in patients with pancreatic cancer. MVT-2163 combines a well-established PET imaging radio-label [Zr-89] with the targeting specificity of the HuMab-5B1 antibody. Preclinical xenograft animal models demonstrated high image resolution of tumors, making MVT-2163 attractive as a potential diagnostic agent for use with the MVT-5873 therapeutic product. This second Phase I trial will evaluate the safety, pharmacokinetics and biodistribution of MVT-2163 in cancer patients. The trial results are also intended to determine the ideal dose and conditions for an optimal PET scan image using the new imaging agent. The first patient in the trial was dosed with MVT-2163 in early July and received PET scans on days 1, 2, 4, and 7. Investigator observations showed scans potentially highlighting smaller metastatic sites not seen on standard CT scans. These results are preliminary and require more patients to confirm. We expect to have the preliminary results of this clinical trial later in the third quarter 2016, with full results expected in 2017 .

[SQUINTZ76]

Great run last couple weeks.

[SanDiegoAlan]

I think that uplisting to NASDAQ is pretty big news. This makes the stock available to mutual funds, ETFs and other institutional investors that are mostly forbidden from investing in OTC securities. I have been waiting for this for a while now. Shareholders also authorized a reverse split in 2015 for this purpose but they didn't pull the trigger on it. The first results on the phase 1 trials are due to be released this quarter also so hopefully that will be the big news to coincide with the uplisting. My fingers are crossed.

[Amatuer17]

The r/s without strong news and financials are not good - the price can come down easily.

Now it depends when they execute r/s -raise new money and give some interim update

With dilution and no new news - the price can slide down post r/s

[Rogerthat1]

In connection with the listing of our shares of common stock on The NASDAQ Capital Market, we intend to implement a 1 for 7.4 reverse split of our issued and outstanding common stock on the date that we price this offering. All per share amounts in this prospectus (other than in our financial statements and the notes thereto) have been retroactively restated to reflect the reverse stock split.

[Rogerthat1]

Ouch

[Rymankoly]

On free options.....

[Rogerthat1]

Insiders loading up

[croptop]

whats next burp (besides a drink?)

[Amatuer17]

Look at 10-k filed on 30th Jun - item no 2
(This is in the news tab of ihub)

Todays filing are amendments to the 10k already filed and resale of securities - this is the securities /warrants already issued.

[ringao]

This didn't jump out at me in the Prospectus filed, is that where you found it?